Australia-wide dispatch

Quantified
Peptides
FOX04-DRI 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

FOX04-DRI

FOXO4-D-Retro-Inverso Peptide. Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About FOX04-DRI

FOXO4-D-Retro-Inverso Peptide

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

FOX04-DRI (FOXO4-D-Retro-Inverso) is a peptidomimetic designed to interfere with the interaction between the FOXO4 transcription factor and p53 in senescent cells. Senescent cells accumulate with age and contribute to tissue dysfunction through the secretion of pro-inflammatory factors (SASP).

Research published in Cell (2017) by Baar et al. demonstrated that FOX04-DRI could selectively induce apoptosis in senescent cells while sparing healthy cells, with treated aged mice showing improvements in physical function, renal function, and fur density. This represented a significant advance in the senolytic peptide research field.

Type
D-retro-inverso peptide · pro-apoptotic
Research Areas
Cellular senescence, apoptosis, ageing research
Target
FOXO4–p53 interaction
Mechanism
Senolytic — apoptosis induction
Key Study
Baar et al., Cell 2017
Selectivity
Senescent cells preferentially
Resistance
D-amino acid form — protease resistant
Research Models
Aged murine models
  1. 01Senescent Cell ClearanceFOX04-DRI is designed to disrupt the interaction between FOXO4 and p53 in senescent cells, enabling p53-mediated apoptosis. Research examines its ability to selectively clear senescent cells without affecting healthy proliferating cells.
  2. 02p53 Apoptotic PathwayResearch has investigated how disrupting the FOXO4-p53 interaction releases p53 to translocate to mitochondria and initiate intrinsic apoptosis specifically in senescent cells that rely on this interaction for survival.
  3. 03Physiological RejuvenationPreclinical studies have examined whether clearance of senescent cell burden using FOX04-DRI restores tissue function, physical performance, and biomarker profiles associated with ageing in murine models.

References

  1. 1Baar MP et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.
  2. 2Kirkland JL et al. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017;65(10):2297-2301.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=FOXO4-DRI+senolytic
  4. 4Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range
NAD+ 500mg, 1000mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

NAD+

$70